# Entrada Therapeutics (TRDA) — Earnings

TRDA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/trda/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$1.04 |
| EPS estimate | −$0.85 |
| EPS surprise | −22.76% |
| Revenue surprise | −79.80% |
| Revenue | $1.9M |
| Revenue estimate | $9.7M |
| Reported | Aug 6, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1689375/000168937525000043/trda-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 6, 2025 | −$0.85 | −$1.04 | -22.76% | $9.7M | $1.9M |
| Q1 2025 | May 8, 2025 | −$0.79 | −$0.42 | 46.74% | $10.2M | $20.6M |
| Q4 2024 | Feb 27, 2025 | −$0.67 | $0.03 | 104.48% | $13.1M | $37.4M |
| Q3 2024 | Nov 5, 2024 | −$0.73 | −$0.35 | 51.92% | $12.3M | $19.6M |
| Q2 2024 | Aug 13, 2024 | $0.36 | $1.55 | 328.89% | $51.9M | $94.7M |
| Q1 2024 | May 7, 2024 | −$0.59 | $0.68 | 214.48% | $15.0M | $59.1M |
| Q4 2023 | Mar 13, 2024 | −$0.17 | −$0.29 | -72.21% | $23.7M | $41.8M |
| Q3 2023 | Nov 7, 2023 | −$0.74 | $1.02 | 238.78% | $9.6M | $43.7M |
| Q2 2023 | Aug 8, 2023 | −$0.69 | −$0.78 | -13.08% | $9.8M | $18.2M |
| Q1 2023 | May 10, 2023 | −$0.65 | −$0.21 | 67.75% | $7.0M | $25.3M |
| Q4 2022 | Mar 6, 2023 | −$0.83 | −$0.79 | 4.51% | — | — |
| Q3 2022 | Nov 7, 2022 | −$0.76 | −$0.80 | -5.26% | — | — |
| Q2 2022 | Aug 11, 2022 | −$0.73 | −$0.74 | -2.07% | — | — |
| Q1 2022 | May 12, 2022 | −$0.66 | −$0.69 | -5.34% | — | — |
| Q4 2021 | Mar 15, 2022 | −$1.29 | −$0.89 | 30.74% | — | — |
| Q3 2021 | Dec 9, 2021 | −$0.87 | −$9.78 | -1024.14% | — | — |

## Frequently Asked Questions

### When did Entrada Therapeutics (TRDA) last report earnings?

Entrada Therapeutics last reported on Aug 6, 2025, covering fiscal Q2 2025.

### Did TRDA beat earnings estimates?

No. Entrada Therapeutics reported EPS of −$1.04 for Q2 2025 against a −$0.85 estimate — a 22.76% miss.

### How much revenue did TRDA report last quarter?

Entrada Therapeutics reported $1.9M in revenue for Q2 2025, against a consensus estimate of $9.7M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).